WallStSmart

CVRx Inc (CVRX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 42678% more annual revenue ($25.27B vs $59.07M). SYK leads profitability with a 13.2% profit margin vs -89.1%. SYK earns a higher WallStSmart Score of 59/100 (C).

CVRX

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -7.47

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVRXUndervalued (+71.4%)

Margin of Safety

+71.4%

Fair Value

$21.26

Current Price

$5.38

$15.88 discount

UndervaluedFair: $21.26Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVRX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.6%8/10

19.6% revenue growth

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

CVRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$156.03M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-180.9%2/10

ROE of -180.9% — below average capital efficiency

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CVRX

The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 19.6% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : CVRX

The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.03 is elevated, increasing financial risk.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CVRX profiles as a growth stock while SYK is a value play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.81 — expect wider price swings.

CVRX is growing revenue faster at 19.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 29/100). CVRX offers better value entry with a 71.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CVRx Inc

HEALTHCARE · MEDICAL DEVICES · USA

CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?